Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 avr. 2024 07h05 HE
|
Travere Therapeutics, Inc.
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
14 mars 2024 15h11 HE
|
Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
11 mars 2024 07h05 HE
|
Travere Therapeutics, Inc.
Travere announces submission of an sNDA to the FDA for conversion of existing US accelerated approval of FILSPARI (sparsentan) in IgAN to full approval.
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
23 févr. 2024 07h05 HE
|
Travere Therapeutics, Inc.
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe ...
IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight
03 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight As potential therapies with novel mechanisms are being...
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
26 sept. 2023 16h30 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics to present abstracts at the 17th International Symposium on IgA Nephropathy.
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
21 sept. 2023 07h30 HE
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year)...
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
08 juin 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
01 avr. 2023 04h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing...
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
17 févr. 2023 16h04 HE
|
Travere Therapeutics, Inc.
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial...